Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)-Reference-Cited by-同舟云学术

Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)

Published:2019-07-11 Issue:5 Volume:25 Page:731-737
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Susen Sophie¹^ORCID,Gruel Yves²,Godier Anne³⁴,Harroche Annie⁵,Chambost Herve⁶,Lasne Dominique⁵^ORCID,Rauch Antoine¹,Roullet Stephanie⁷,Fontana Pierre⁸⁹^ORCID,Goudemand Jenny¹,de Maistre Emmanuel¹⁰,Chamouard Valerie¹¹,Wibaut Bénédicte¹,Albaladejo Pierre¹²¹³,Négrier Claude¹¹^ORCID

Affiliation:

1. CHU Lille Université de Lille Lille France

2. Département d’Hématologie‐Hémostase Hôpital Universitaire de Tours Tours France

3. Service d'Anesthésie Réanimation, AP‐HP Hôpital Européen Georges Pompidou Paris France

4. Inserm UMR‐S1140, Université Paris Descartes Sorbonne Paris Cité Paris France

5. CRC MHC, Service d’Hématologie Clinique Hôpital Universitaire Necker Enfants Malades, Laboratoire d’Hématologie Générale, Hôpital Necker AP‐HP Paris France

6. APHM, Hôpital d‘Enfants La Timone, Service d'Hématologie Oncologie Pédiatrique et Aix Marseille Univ, INSERM INRA, C2VN Marseille France

7. Inserm U 1034, Service Anesthésie‐Réanimation Pellegrin, Université de Bordeaux CHU de Bordeaux Bordeaux France

8. Service d’Angiologie et d’Hémostase, Département de Médecine Hôpitaux Universitaires de Genève Genève Switzerland

9. Geneva Platelet Group, Faculté de Médecine Université de Genève Genève Switzerland

10. Service d’Hématologie Biologique — Secteur Hémostase, Plateau Technique de Biologie CHU Dijon‐Bourgogne Dijon France

11. Unité d’Hémostase Clinique, Louis Pradel Hospital University Claude Bernard Lyon France

12. Département d’Anesthésie‐Réanimation CHU Grenoble‐Alpes Grenoble France

13. ThEMAS, TIMC, UMR CNRS 5525 Université Grenoble‐Alpes Grenoble France

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13817

Reference18 articles.

1. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

2. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

3. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

4. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

5. Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates;Research and Practice in Thrombosis and Haemostasis;2024-05

2. Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab;TH Open;2024-04

3. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence;Haemophilia;2024-01-30

4. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors;TH Open;2024-01

5. Gestion des troubles de l'hémostase congénitaux;Médecine Péri-Opératoire;2024